MAVYRET 100-40 MG TABLET
FDA nonproprietary name: glecaprevir and pibrentasvir
For 30 tablets
Pharmacies pay
$4,589.50 filed
30 × $152.98338 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$4,675.12 filed
30 × $155.83739 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
1.0× estimated
Medicare paid about what pharmacies pay.
Part D averages every strength and form sold under “Mavyret” / “Glecaprevir/Pibrentasvir” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$5,282.93 estimated
$4,589.50 + $688.43 (15%) + $5.00 fee per fill = $5,282.93
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
MAVYRET 100-40 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as glecaprevir and pibrentasvir, under the trade name “Mavyret”.
FDA gives its dosage form as tablet, film coated and its route as oral.
The labeler, the company named on the label, is AbbVie Inc.
FDA lists it under 2 Established Pharmacologic Classes: Hepatitis C Virus NS3/4A Protease Inhibitor and Hepatitis C Virus NS5A Inhibitor.
The NADAC file of 2026-10-14 prices it under 3 NDCs (National Drug Codes).
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $4,589.50 for 30 tablets (30 × $152.98338 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.
What NADAC measures · Why 30 tablets · NADAC explanation codes
All 3 NDCs
- 00074-2625-04 · AbbVie Inc. · $152.98338 per EA · eff. 2026-09-23 filed
- 00074-2625-28 · AbbVie Inc. · $152.98338 per EA · eff. 2026-09-23 filed
- 00074-2625-84 · AbbVie Inc. · $152.98338 per EA · eff. 2026-09-23 filed
What Medicare paid
Medicare Part D paid $4,675.12 for 30 tablets, at an average of $155.83739 per EA in 2024 (2024-01-01 to 2024-12-31) for “Mavyret” and “Glecaprevir/Pibrentasvir”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 12,457 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for MAVYRET 100-40 MG TABLET labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Mavyret / Glecaprevir/Pibrentasvir: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.